Skip to main content
Premium Trial:

Request an Annual Quote

Fanelli Appointed VP Sales For Base4 Bioinformatics


MISSISSAUGA, Ont.--Base4 Bioinformatics announced that Joe Fanelli joined the pharmaceutical informatics company as vice-president of sales and marketing. Fanelli, who was most recently vice-president for Quantum Biotechnologies, will be stationed at Base4's US headquarters in San Diego, Calif. Fanelli has also held senior management positions in early-stage and major biomedical firms including Roche Diagnostics, Beckman, Cetus, Microgenics, and Cangene.

Martin Sumner Smith, Base4's president, said that, now that the company has invested heavily in product development, Fanelli will build the sales and marketing infrastructure to propel Base4 into the "prominent supplier position for the bioinformatics market." Base4's Pharmatrix software product provides collaborative knowledge and project management capabilities to pharmaceutical research organizations. The company also develops custom databases for unique applications in pharmaceutical and biotechnology companies.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.